<DOC>
	<DOCNO>NCT00335140</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some find cancer cell kill carry cancer-killing substance . Others interfere ability cancer cell grow spread . Drugs use chemotherapy , methotrexate , leucovorin , vincristine , procarbazine , dexamethasone , cytarabine , work different way stop growth cancer cell , either kill cell stop divide . Giving rituximab together combination chemotherapy may kill cancer cell . PURPOSE : This phase II trial study well give rituximab together combination chemotherapy work treat patient primary central nervous system ( CNS ) lymphoma .</brief_summary>
	<brief_title>Rituximab Combination Chemotherapy Treating Patients With Primary Central Nervous System Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine complete response rate . Secondary - Determine progression-free survival patient . - Determine proportion progression-free overall survival patient . - Determine rituximab cerebrospinal fluid pharmacokinetics ( patient require intrathecal chemotherapy ) . OUTLINE : This multicenter study . Patients receive rituximab IV 3 time weekly week 1-4 ; high-dose methotrexate IV 2 hour week 1 , 3 , 5 , 9 ; oral IV leucovorin calcium every 6 hour 12 dos begin 24 hour start methotrexate week 1 , 3 , 5 , 9 ; vincristine IV week 1 , 3 , 5 , 7 , 9 ; oral procarbazine hydrochloride daily day 1-7 week 1 , 5 , 9 ; oral dexamethasone daily week 1-6 ; cytarabine IV 2 hour twice weekly week 11 14 . Patients positive cerebrospinal fluid also receive methotrexate intrathecally oral leucovorin calcium every 12 hour 8 dos begin 24 hour start methotrexate week 2 , 4 , 6 , 8 , 10 . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 43 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonHodgkin 's lymphoma brain biopsy Patients inconclusive biopsy patient candidate biopsy must typical CT scan MRI brain AND meet ≥ 1 follow criterion : Positive cerebrospinal fluid cytology lymphoma OR monoclonal lymphoid population define cell surface marker immunoglobulin gene rearrangement study Biopsyproven involvement vitreous uvea cell apparent posterior chamber vitreous ophthalmological examination Bideminsionally measurable disease , define contrastenhancing tumor ≥ 1 cm pretreatment MRI/CT scan Meningeal vitreous involvement constitutes evaluable measurable disease If excisional , rather needle biopsy do , measurable disease must present postoperative scan PETCT scan allow No systemic lymphoma ( determined preregistration CT scan physical examination ) PATIENT CHARACTERISTICS : ECOG performance status 03 Absolute granulocyte count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Bilirubin ≤ upper limit normal ( ULN ) SGOT ≤ 2.0 time ULN Creatinine clearance ≥ 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No HIV1 positivity No malignancy within past 5 year except basal cell skin cancer carcinoma situ No preexist immunodeficiency No hepatitis B surface antigen positivity PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy primary central nervous system lymphoma No prior organ bone marrow transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
</DOC>